The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
Pharmaceuticals · 09.01.2023 · 16 (1) · 94
DOI: 10.3390/ph16010094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 09.01.2023. Verfasst von Victor M Matias-Barrios und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institute of Health Research (CIHR).
Abstract (Originalsprache)
DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA topology through the generation of temporary double-strand breaks. Cancer cells acquire enhanced Top2 functions to cope with the stress generated by transcription and DNA replication during rapid cell division since cancer driver genes such as Myc and EZH2 hijack Top2 in order to realize their oncogenic transcriptomes for cell growth and tumor progression. Inhibitors of Top2 are therefore designed to target Top2 to trap it on DNA, subsequently causing protein-linked DNA breaks, a halt to the cell cycle, and ultimately cell death. Despite the effectiveness of these inhibitors, cancer cells can develop resistance to them, thereby limiting their therapeutic utility. To maximize the therapeutic potential of Top2 inhibitors, combination therapies to co-target Top2 with DNA damage repair (DDR) machinery and oncogenic pathways have been proposed to induce synthetic lethality for more thorough tumor suppression. In this review, we will discuss the mode of action of Top2 inhibitors and their potential applications in cancer treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.
- School of Medicine and Health Sciences, Tecnologico de Monterrey, Avenida Eugenio Garza Sada 2501, Monterrey 64849, Mexico.
ORCID-Profile: Victor M Matias-Barrios, Xuesen Dong
Förderung
- CIHR
- Canadian Institute of Health Research (CIHR)
Zitieren
APA
Matias-Barrios, V. M., & Dong, X. (2023). The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals, 16(1), 94. https://doi.org/10.3390/ph16010094
Vancouver
Matias-Barrios VM, Dong X. The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals. 2023;16(1):94. doi:10.3390/ph16010094
BibTeX
@article{MatiasBarrios2023,
author = {Matias-Barrios, Victor M and Dong, Xuesen},
title = {The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {1},
pages = {94},
doi = {10.3390/ph16010094}
}
EUVIMED